Biotech News
GSK’s Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency
Over 25 million people in Europe have received GSK’s shingles vaccine since 2018.
Related news
GSKGSK plc2026-09-10 07:00 EST
GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan
BMYBMYBristol-Myers Squibb Company2026-08-29 15:00 EST
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
GSKGSK plc2026-08-24 07:01 EST
Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
CRSPCRISPR Therapeutics2026-08-28 14:31 EST
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
KURAKura Oncology2026-09-01 11:15 EST
Kura Oncology to Participate in Three Investor Conferences in September
ANABAnaptysBio, Inc.2026-09-01 20:15 EST
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
LYELLyell Immunopharma2026-09-14 11:00 EST
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
SANASana Biotechnology2026-09-01 20:05 EST
Sana Biotechnology to Present at September 2026 Investor Conferences
BCRXBioCryst Pharmaceuticals2026-09-01 11:00 EST
BioCryst to Present at Upcoming Investor Conference
SRPTSarepta Therapeutics2026-08-31 20:30 EST
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
GSK plc
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...
Recent company news
GSKGSK plc2026-10-06 14:00 EST
ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia
GSKGSK plc2026-09-15 14:21 EST
GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences
GSKGSK plc2026-09-13 19:30 EST
GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer
GSKGSK plc2026-09-13 08:00 EST
Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China
GSKGSK plc2026-09-10 07:00 EST
GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan
Stock data
- Close
- 46.60 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States